[go: up one dir, main page]

MX2018001315A - Inhibidores de fucosidasa. - Google Patents

Inhibidores de fucosidasa.

Info

Publication number
MX2018001315A
MX2018001315A MX2018001315A MX2018001315A MX2018001315A MX 2018001315 A MX2018001315 A MX 2018001315A MX 2018001315 A MX2018001315 A MX 2018001315A MX 2018001315 A MX2018001315 A MX 2018001315A MX 2018001315 A MX2018001315 A MX 2018001315A
Authority
MX
Mexico
Prior art keywords
inhibitors
fucosidase inhibitors
tumors
fucosidase
liver
Prior art date
Application number
MX2018001315A
Other languages
English (en)
Other versions
MX381092B (es
Inventor
C Zankel Todd
Louise Isbell Sara
Anne Ko Amanda
Original Assignee
Horizon Orphan Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Horizon Orphan Llc filed Critical Horizon Orphan Llc
Publication of MX2018001315A publication Critical patent/MX2018001315A/es
Publication of MX381092B publication Critical patent/MX381092B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere, en general, a compuestos que son de utilidad como inhibidores de las enzimas fucosidasa y a métodos y composiciones para el tratamiento de tumores o cánceres, tales como trastornos hepáticos y tumores de hígado (por ejemplo, carcinoma hepatocelular), con un compuesto descrito en la presente.
MX2018001315A 2015-07-30 2016-07-29 Inhibidores de fucosidasa. MX381092B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562199194P 2015-07-30 2015-07-30
PCT/US2016/044607 WO2017019925A1 (en) 2015-07-30 2016-07-29 Fucosidase inhibitors

Publications (2)

Publication Number Publication Date
MX2018001315A true MX2018001315A (es) 2018-08-15
MX381092B MX381092B (es) 2025-03-12

Family

ID=56616083

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001315A MX381092B (es) 2015-07-30 2016-07-29 Inhibidores de fucosidasa.

Country Status (15)

Country Link
US (2) US9951013B2 (es)
EP (1) EP3328832B1 (es)
JP (2) JP6981961B2 (es)
KR (1) KR20180030699A (es)
CN (1) CN107848970B (es)
AR (1) AR105540A1 (es)
AU (2) AU2016298324A1 (es)
BR (1) BR112018000961A2 (es)
CA (1) CA2992033A1 (es)
IL (1) IL256662B (es)
MX (1) MX381092B (es)
RU (1) RU2765202C2 (es)
TW (1) TWI777923B (es)
WO (1) WO2017019925A1 (es)
ZA (1) ZA201800638B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546423B2 (en) 2005-05-18 2013-10-01 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
CN102202649A (zh) 2008-10-07 2011-09-28 Mpex医药有限公司 用于改进的药物动力学的氟喹诺酮气雾剂制剂
PL2346509T3 (pl) 2008-10-07 2021-03-08 Horizon Orphan Llc Lewofloksacyna w postaci aerozolu dla zmniejszania stanu zapalnego płuc
KR20120100904A (ko) 2009-09-04 2012-09-12 엠펙스 파마슈티컬즈, 인코포레이티드 낭포성 섬유증을 치료하기 위한 에어로졸화된 레보플록사신의 용도
CN107848970B (zh) 2015-07-30 2021-07-06 地平线孤儿病有限责任公司 岩藻糖苷酶抑制剂
KR20220115998A (ko) * 2019-12-19 2022-08-19 메르크 파텐트 게엠베하 단백질의 글리코실화 프로파일을 조절하기 위한 방법 및 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US5186941A (en) 1983-05-06 1993-02-16 Vestar, Inc. Vesicle formulation for the controlled release of therapeutic agents
US5153325A (en) 1989-06-27 1992-10-06 Monsanto Company Fucosidase inhibitor
US5100797A (en) 1989-06-27 1992-03-31 Monsanto Company Fucosidase inhibitors
US5017704A (en) 1989-06-27 1991-05-21 Monsanto Company Fucosidase inhibitor
US5096909A (en) 1989-06-27 1992-03-17 Monsanto Company Fucosidase inhibitor
US5240707A (en) 1990-04-12 1993-08-31 Merrell Dow Pharma Alpha-mannosidase and fucosidase inhibitors
EP0741741B1 (en) * 1994-01-26 2002-08-28 Novartis AG Modified oligonucleotides
TW492882B (en) 1997-11-28 2002-07-01 Caleb Pharmaceuticals Inc Cholinergic antagonist plaster composition
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
EP2323652A2 (en) * 2008-08-06 2011-05-25 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
KR101784539B1 (ko) * 2010-01-28 2017-10-11 랩터 파마슈티컬스 인코포레이티드 수용체 결합 단백질(ｒａｐ) 펩타이드-푸코시다제 억제제 접합체를 이용한 간 질환의 치료방법
BR112014014808A2 (pt) * 2011-12-22 2018-09-25 Centogene Ip Gmbh combinações de um composto que tem a capacidade de reorganizar uma enzima lisossômica e ambroxol e/ou um derivado de ambroxol, sua utilização, preparação farmacêutica e seu método de preparação
WO2014032184A1 (en) * 2012-08-31 2014-03-06 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
CN107848970B (zh) 2015-07-30 2021-07-06 地平线孤儿病有限责任公司 岩藻糖苷酶抑制剂

Also Published As

Publication number Publication date
CA2992033A1 (en) 2017-02-02
ZA201800638B (en) 2022-08-31
RU2018107143A (ru) 2019-08-29
IL256662B (en) 2021-06-30
RU2018107143A3 (es) 2019-12-27
MX381092B (es) 2025-03-12
KR20180030699A (ko) 2018-03-23
EP3328832A1 (en) 2018-06-06
JP6981961B2 (ja) 2021-12-17
US10308607B2 (en) 2019-06-04
CN107848970A (zh) 2018-03-27
CN107848970B (zh) 2021-07-06
JP2021152078A (ja) 2021-09-30
WO2017019925A1 (en) 2017-02-02
AR105540A1 (es) 2017-10-11
IL256662A (en) 2018-02-28
TWI777923B (zh) 2022-09-21
BR112018000961A2 (pt) 2018-09-18
RU2765202C2 (ru) 2022-01-26
TW201713620A (zh) 2017-04-16
US20170029376A1 (en) 2017-02-02
AU2020289858A1 (en) 2021-01-28
JP2018522023A (ja) 2018-08-09
US20190077756A1 (en) 2019-03-14
EP3328832B1 (en) 2021-03-03
US9951013B2 (en) 2018-04-24
AU2016298324A1 (en) 2018-01-25

Similar Documents

Publication Publication Date Title
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
PH12018500718A1 (en) Compounds useful as modulators of trpm8
MX2022009148A (es) Composiciones y metodos para el tratamiento de hemoglobinopatias.
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
ECSP18049420A (es) Composiciones novedosas, usos y métodos para hacerlas
UY37018A (es) Inhibidores bicíclicos de pad4
UY36419A (es) Composiciones farmacéuticas que contienen anticuerpos anti-cd38 para el tratamiento de la leucemia mieloide aguda
CO2017012947A2 (es) Inhibidores de tirosina-cinasas
BR112018010089A2 (pt) composições compreendendo cepas bacterianas
JOP20190194A1 (ar) مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان
MX2017012699A (es) Compuestos heterociclicos como inhibidores de demetilasa 1 especifica de lisina (lsd1).
CR20150316A (es) Compuestos y sus métodos de empleo
MX2015012401A (es) Composiciones y metodos de alterar niveles de colesterol.
MX2017016322A (es) Metodos para tratar tumores de celulas epitelioides.
CR20150483A (es) Composiciones y métodos para el diagnóstico y tratamiento del cáncer hepático
MX2015011281A (es) Composiciones de inh-c1 y metodos para la prevencion y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa.
UY37017A (es) Inhibidores aza-bencimidazol de pad4
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX2018007155A (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj).
MX2018001315A (es) Inhibidores de fucosidasa.
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
PH12017501879A1 (en) Methods for treating cancer
MX2015010728A (es) Metodos y composiciones para el tratamiento de leucemia.
MX369857B (es) Pirazinas moduladoras de receptor 6 acoplado a la proteina g (gpr6).
MX388409B (es) Composiciones y metodos para tratar canceres.